Factor XI inhibitors versus direct oral anticoagulants for stroke prevention in atrial fibrillation: a systematic review of efficacy and safety

Razieh Parizad , Juniali Hatwal , Haleh Bodagh , Akash Batta , Bishav Mohan

Exploration of Neuroprotective Therapy ›› 2026, Vol. 6 ›› Issue (1) : 1004148

PDF (3208KB)
Exploration of Neuroprotective Therapy ›› 2026, Vol. 6 ›› Issue (1) :1004148 DOI: 10.37349/ent.2026.1004148
Systematic Review
research-article
Factor XI inhibitors versus direct oral anticoagulants for stroke prevention in atrial fibrillation: a systematic review of efficacy and safety
Author information +
History +
PDF (3208KB)

Abstract

Background: Atrial fibrillation (AF) substantially increases the risk of ischemic stroke (IS), underscoring the need for effective anticoagulation strategies. Direct oral anticoagulants (DOACs) have largely supplanted vitamin K antagonists (VKAs) due to their favorable safety profile and ease of use. Factor XI (FXI) inhibitors, which target the intrinsic coagulation pathway, are emerging as potential alternatives that may offer reduced bleeding risk. This systematic review evaluates the efficacy and safety of FXI inhibitors compared with DOACs for stroke prevention in AF. Methods: A total of 20 studies fulfilled the inclusion criteria, comprising 11 randomized controlled trials (RCTs), five systematic reviews or meta-analyses, and four narrative, cohort, or modeling studies. Eligible investigations compared FXI inhibitors with DOACs in patients diagnosed with AF. The primary outcomes assessed were stroke or systemic embolism, major bleeding, and all-cause mortality. Methodological quality was evaluated according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) framework, the revised Cochrane Risk of Bias 2 (RoB 2) tool for RCTs, and the Newcastle-Ottawa Scale (NOS). Results: FXI inhibitors were associated with a significant reduction in major bleeding [relative risk (RR) 0.31; 95% confidence interval (CI) 0.21–0.46] and clinically relevant non-major bleeding (RR 0.66; 95% CI 0.47–0.93) compared with DOACs. Conversely, FXI inhibitors demonstrated an increased risk of stroke or systemic embolism (RR 3.17; 95% CI 2.18–4.62), as observed in the OCEANIC-AF trial [hazard ratio (HR) 3.79; 95% CI 2.46–5.83]. No significant difference was noted in all-cause mortality (RR 0.85; 95% CI 0.67–1.08). Limited evidence suggests that FXI inhibitors may also reduce bleeding-related hospitalizations. Discussion: FXI inhibitors provide a favorable bleeding profile but are less effective than DOACs for stroke prevention in patients with AF. Further long-term RCTs are warranted to delineate their role, particularly in populations at high risk of bleeding.

Keywords

atrial fibrillation / stroke prevention / factor XI inhibitors / direct oral anticoagulants / bleeding risk / thromboembolism / anticoagulation therapy

Cite this article

Download citation ▾
Razieh Parizad, Juniali Hatwal, Haleh Bodagh, Akash Batta, Bishav Mohan. Factor XI inhibitors versus direct oral anticoagulants for stroke prevention in atrial fibrillation: a systematic review of efficacy and safety. Exploration of Neuroprotective Therapy, 2026, 6 (1) : 1004148 DOI:10.37349/ent.2026.1004148

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

Kornej J, Börschel CS, Benjamin EJ, Schnabel RB. Epidemiology of Atrial Fibrillation in the 21st Century: Novel Methods and New Insights. Circ Res. 2020; 127: 4-20.

[2]

GBD 2019 Stroke Collaborators. Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurol. 2021; 20: 795-820.

[3]

Lip GYH, Banerjee A, Boriani G, Chiang CE, Fargo R, Freedman B, et al. Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report. Chest. 2018; 154: 1121-201.

[4]

Aarnink E, Zabern M, Boersma L, Glikson M. Mechanisms and Prediction of Ischemic Stroke in Atrial Fibrillation Patients. J Clin Med. 2023; 12: 6491.

[5]

Escudero-Martínez I, Morales-Caba L, Segura T. Atrial fibrillation and stroke: A review and new insights. Trends Cardiovasc Med. 2023; 33: 23-9.

[6]

Migdady I, Russman A, Buletko AB. Atrial Fibrillation and Ischemic Stroke: A Clinical Review. Semin Neurol. 2021; 41: 348-64.

[7]

Batta A, Sharma YP, Hatwal J, Panda P, Kumar BGV, Bhogal S. Predictors of dementia amongst newly diagnosed non-valvular atrial fibrillation patients. Indian Heart J. 2022; 74: 505-9.

[8]

Batta A, Hatwal J, Sharma YP. Assessment of Coronary Artery Disease in Non-Valvular Atrial Fibrillation: Is This Light at the End of the Tunnel? Vasc Health Risk Manag. 2024; 20: 493-9.

[9]

Sposato LA, Chaturvedi S, Hsieh C, Morillo CA, Kamel H. Atrial Fibrillation Detected After Stroke and Transient Ischemic Attack: A Novel Clinical Concept Challenging Current Views. Stroke. 2022; 53: e94-103.

[10]

Choi SE, Sagris D, Hill A, Lip GYH, Abdul-Rahim AH. Atrial fibrillation and stroke. Expert Rev Cardiovasc Ther. 2023; 21: 35-56.

[11]

Santangelo G, Bursi F, Faggiano A, Moscardelli S, Simeoli PS, Guazzi M, et al. The Global Burden of Valvular Heart Disease: From Clinical Epidemiology to Management. J Clin Med. 2023; 12: 2178.

[12]

Lee JM, Kim TH, Park JK, Joung B, Choi EK. 2021 Korean Heart Rhythm Society Guidelines for Screening and Management of Subclinical Atrial Fibrillation. Korean J Med. 2021; 96: 76-84.

[13]

Buja A, Rebba V, Montecchio L, Renzo G, Baldo V, Cocchio S, et al. The Cost of Atrial Fibrillation: A Systematic Review. Value Health. 2024; 27: 527-41.

[14]

Linz D, Gawalko M, Betz K, Hendriks JM, Lip GYH, Vinter N, et al. Atrial fibrillation: epidemiology, screening and digital health. Lancet Reg Health Eur. 2024; 37: 100786.

[15]

Steffel J, Collins R, Antz M, Cornu P, Desteghe L, Haeusler KG, et al. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace. 2021; 23: 1612-76.

[16]

López-López JA, Sterne JAC, Thom HHZ, Higgins JPT, Hingorani AD, Okoli GN, et al. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis. BMJ. 2017; 359: j5058.

[17]

McIntyre WF, Benz AP, Becher N, Healey JS, Granger CB, Rivard L, et al. Direct Oral Anticoagulants for Stroke Prevention in Patients With Device-Detected Atrial Fibrillation: A Study-Level Meta-Analysis of the NOAH-AFNET 6 and ARTESiA Trials. Circulation. 2024; 149: 981-8.

[18]

Zortea V, Curvello KD, Pilger D, Douros A, Leal LF, da Silva Sempé T, et al. Adherence and Quality of Life in Non-Valvular Atrial Fibrillation With Direct Oral Anticoagulants Versus Vitamin K Antagonists: A Systematic Review. Int J Cardiovasc Sci. 2023; 36: e20220115.

[19]

Campos-Staffico AM, Jacoby JP, Dorsch MP, Limdi NA, Barnes GD, Luzum JA. Risk scores for major bleeding from direct oral anticoagulants: comparing predictive performance in patients with atrial fibrillation. Res Pract Thromb Haemost. 2023; 8: 102285.

[20]

Carlin S, Jakovac M, Budaj A, Eikelboom J. Factor XI inhibition in cardiovascular disease. Pol Arch Intern Med. 2024; 134: 16799.

[21]

Raffo C, Leo GD, Capodanno D. Factor XI inhibitors and atrial fibrillation: imminent breakthrough or false start? Eur Heart J Suppl. 2025; 27: iii46-53.

[22]

Galli M, Laborante R, Ortega-Paz L, Franchi F, Rollini F, DʼAmario D, et al. Factor XI Inhibitors in Early Clinical Trials: A Meta-analysis. Thromb Haemost. 2023; 123: 576-84.

[23]

Piccini JP, Caso V, Connolly SJ, Fox KAA, Oldgren J, Jones WS ; PACIFIC-AF Investigators. Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study. Lancet. 2022; 399: 1383-90.

[24]

Thomas D, Kanefendt F, Schwers S, Unger S, Yassen A, Boxnick S. First evaluation of the safety, pharmacokinetics, and pharmacodynamics of BAY 2433334, a small molecule targeting coagulation factor XIa. J Thromb Haemost. 2021; 19: 2407-16.

[25]

Ruff CT, Patel SM, Giugliano RP, Morrow DA, Hug B, Kuder JF, et al.; AZALEA-TIMI 71 Investigators. Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation. N Engl J Med. 2025; 392: 361-71.

[26]

Emara A, Gadelmawla AF, Emara M, Murad MR, Elgendy MS, Ellebedy M, et al. Factor XI/XIa inhibitors versus direct oral anticoagulants in atrial fibrillation with stroke risk: a GRADE-assessed meta-analysis of randomized controlled trials. Naunyn Schmiedebergs Arch Pharmacol. 2025; 398: 14603-16.

[27]

Piccini JP, Patel MR, Steffel J, Ferdinand K, Gelder ICV, Russo AM, et al.; OCEANIC-AF Steering Committee and Investigators. Asundexian versus Apixaban in Patients with Atrial Fibrillation. N Engl J Med. 2025; 392: 23-32.

[28]

Shoamanesh A, Mundl H, Smith EE, Masjuan J, Milanov I, Hirano T, et al.; PACIFIC-Stroke Investigators. Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial. Lancet. 2022; 400: 997-1007.

[29]

Markides RIL, Koolaji S, Leader JH, Farag M, Gorog DA. Safety of factor XI inhibitors compared to factor X inhibitors in atrial fibrillation: a systematic review and meta-analysis. J Thromb Thrombolysis. 2025; 58: 761-73.

[30]

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372: n71.

[31]

Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019; 366: l4898.

[32]

Luchini C, Stubbs B, Solmi M, Veronese N. Assessing the quality of studies in meta-analyses: Advantages and limitations of the Newcastle Ottawa Scale. World J Meta-Analysis. 2017; 5: 80-4.

[33]

Xue Z, Liao S, Fan H, Shen Y, Nie Z. A Systematic Review of Factor XI/XIa Inhibitors Versus Direct Oral Anticoagulants in Patients with Atrial Fibrillation. Clin Appl Thromb Hemost. 2025; 31: 10760296251335967.

[34]

Vinogradova Y, Coupland C, Hill T, Hippisley-Cox J. Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care. BMJ. 2018; 362: k2505.

[35]

Coleman CI, Antz M, Bowrin K, Evers T, Simard EP, Bonnemeier H, et al. Real-world evidence of stroke prevention in patients with nonvalvular atrial fibrillation in the United States: the REVISIT-US study. Curr Med Res Opin. 2016; 32: 2047-53.

[36]

Camm AJ, Amarenco P, Haas S, Hess S ; XANTUS Investigators. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J. 2016; 37: 1145-53.

[37]

Rao SV, Kirsch B, Bhatt DL, Budaj A, Coppolecchia R, Eikelboom J, et al.; PACIFIC AMI Investigators. A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction. Circulation. 2022; 146: 1196-206.

[38]

Sharma M, Molina CA, Toyoda K, Bereczki D, Bangdiwala SI, Kasner SE, et al. Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet Neurol. 2024; 23: 46-59.

[39]

Perera V, Wang Z, Luettgen J, Li D, DeSouza M, Cerra M, et al. First-in-human study of milvexian, an oral, direct, small molecule factor XIa inhibitor. Clin Transl Sci. 2022; 15: 330-42.

[40]

de Alcântara JPTL, Götz GWXDR, Amaral PEO, Cecchetti G, Marques GL. Factor XI inhibitors versus direct oral anticoagulants for the prevention of thromboembolic events and safety in patients with atrial fibrillation: A systematic review and meta-analysis of randomized controlled trials. Heart Lung. 2026; 78: 102739.

[41]

Franco-Moreno A, Muñoz-Rivas N, Torres-Macho J, Bustamante-Fermosel A, Ancos-Aracil CL, Madroñal-Cerezo E. Systematic review of clinical trials on antithrombotic therapy with factor XI inhibitors. Rev Clin Esp (Barc). 2024; 224: 167-77.

[42]

Parsa S, Jain SS, Akinrimisi O, Lam CSP, Mahaffey KW. Milvexian: An Oral, Bioavailable Factor XIa Inhibitor. Cardiol Ther. 2024; 13: 645-61.

[43]

Jain SS, Mahaffey KW, Pieper KS, Shimizu W, Potpara T, Ruff CT, et al.; LIBREXIA AF Trial Investigators and Committees. Milvexian vs apixaban for stroke prevention in atrial fibrillation: The LIBREXIA atrial fibrillation trial rationale and design. Am Heart J. 2024; 277: 145-58.

[44]

Shahid S, Iqbal M, Shahabi M, Ali MA, Khan A, Shahid MA, et al. Factor XIa Inhibitors Versus Direct Oral Anticoagulants for Atrial Fibrillation: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Cardiovasc Drugs Ther. 2026; 40: 725-34.

[45]

Patel SM, Giugliano RP, Morrow DA, Goodrich EL, Hug B, Parkar S, et al. Factor XI Inhibition with Abelacimab in Atrial Fibrillation Across the Spectrum of Bleeding Risk. JACC. 2025; 85: 28.

[46]

Zhou W, Bozenhardt E, Alexander GE, Zierhut ML, Merali S, Ajavon-Hartmann A, et al. Quantitative Model-Informed Dose Selection for a Milvexian Phase III Study in Patients With Atrial Fibrillation. Clin Pharmacol Ther. 2026; 119: 139-46.

[47]

Al Said S, Patel SM, Giugliano RP, Morrow DA, Goodrich EL, Murphy SA, et al. Abelacimab Versus Rivaroxaban in Patients With Atrial Fibrillation on Antiplatelet Therapy: A Prespecified Analysis of the AZALEA-TIMI 71 Trial. Circulation. 2025; 152: 290-6.

[48]

Gallagher C, Nyfort-Hansen K, Rowett D, Wong CX, Middeldorp ME, Mahajan R, et al. Polypharmacy and health outcomes in atrial fibrillation: a systematic review and meta-analysis. Open Heart. 2020; 7: e001257.

[49]

Königsbrügge O, Simon A, Domanovits H, Pabinger I, Ay C. Thromboembolic events, bleeding, and drug discontinuation in patients with atrial fibrillation on anticoagulation: a prospective hospital-based registry. BMC Cardiovasc Disord. 2016; 16: 254.

[50]

Benzimra M, Bonnamour B, Duracinsky M, Lalanne C, Aubert J, Chassany O, et al. Real-life experience of quality of life, treatment satisfaction, and adherence in patients receiving oral anticoagulants for atrial fibrillation. Patient Prefer Adherence. 2018; 12: 79-87.

[51]

Faizan MA, Rehman T, Dandamudi M, Menon JA, Ferrara VZ, Kholeif Z, et al. Dose-Response Efficacy and Safety of Factor XI/XIa Inhibitors in Atrial Fibrillation; a Systematic Review and Meta-Analysis With Subgroup Exploration and Trial Sequential Validation. Clin Cardiol. 2026; 49: e70263.

[52]

Cichewicz A, Jawla S, Zuchinali P, Akin-Fajiye M, Massierer D, Porto I, et al. Real-world evidence comparing oral anticoagulants for NVAF in Europe: a systematic review and network meta-analysis. Future Cardiol. 2025; 21: 371-90.

PDF (3208KB)

0

Accesses

0

Citation

Detail

Sections
Recommended

/

〈 〉